This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AQXP Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP) Get AQXP alerts:Sign Up Key Stats Today's Range$20.96▼$22.0750-Day Range$3.68▼$4.0352-Week Range$2.00▼$3.84Volume89,409 shsAverage Volume239,362 shsMarket Capitalization$508.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Read More Receive AQXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aquinox Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AQXP Stock News HeadlinesMirum Pharmaceuticals, Inc. (MIRM)February 11, 2024 | finance.yahoo.comWhy Aquinox Pharma (AQXP) Stock Might be a Great PickSeptember 24, 2023 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 27 at 1:00 AM | InvestorPlace (Ad)Aquinox Pharmaceuticals (AQXP) Stock Jumping in After-Hours Trading Following Earnings BeatJuly 26, 2023 | thestreet.comAquinox Pharma's lead product candidate flunks mid-stage trial in COPD; shares plummet 70%June 9, 2022 | seekingalpha.comSee More Headlines AQXP Stock Analysis - Frequently Asked Questions How were Aquinox Pharmaceuticals' earnings last quarter? Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) announced its earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.43. What other stocks do shareholders of Aquinox Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), XOMA Royalty (XOMA), Alnylam Pharmaceuticals (ALNY) and NVIDIA (NVDA). Company Calendar Last Earnings11/08/2018Today9/27/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AQXP CIK1404644 Webwww.aqxpharma.com Phone604-629-9223FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.13% Return on Assets-28.08% Debt Debt-to-Equity RatioN/A Current Ratio63.17 Quick Ratio63.17 Sales & Book Value Annual Sales$25 million Price / Sales20.35 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book6.99Miscellaneous Outstanding Shares23,540,000Free FloatN/AMarket Cap$508.70 million OptionableNot Optionable Beta-7.37 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:AQXP) was last updated on 9/27/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
